临床心身疾病杂志
臨床心身疾病雜誌
림상심신질병잡지
JOURNAL OF CLINICAL PSYCHOSOMATIC DISEASES
2015年
4期
50-52
,共3页
首发精神分裂症%哌罗匹隆%利培酮%阳性与阴性症状量表%副反应量表
首髮精神分裂癥%哌囉匹隆%利培酮%暘性與陰性癥狀量錶%副反應量錶
수발정신분렬증%고라필륭%리배동%양성여음성증상량표%부반응량표
First-episode schizophrenia%perospirone%risperidone%PANSS%TESS
目的：探讨哌罗匹隆与利培酮治疗首发精神分裂症患者的临床疗效和安全性。方法将120例首发精神分裂症患者随机分为两组，研究组口服哌罗匹隆治疗，对照组口服利培酮治疗，观察8周。采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降（ P＜0．05或0．01），治疗8周末研究组总有效率为83．3％，对照组为81．7％，两组比较差异无显著性（χ2＝0．06，P＞0．05）。研究组不良反应发生率为56．7％，对照组为53．3％，两组比较差异无显著性（χ2＝0．13，P＞0．05），但研究组体质量增加、月经改变及泌乳、性欲改变等不良反应发生率低于对照组。结论哌罗匹隆与利培酮治疗首发精神分裂症疗效显著，安全性高，依从性好，但哌罗匹隆较少引起内分泌改变和体质量增加，更适用于女性首发精神分裂症患者。
目的：探討哌囉匹隆與利培酮治療首髮精神分裂癥患者的臨床療效和安全性。方法將120例首髮精神分裂癥患者隨機分為兩組，研究組口服哌囉匹隆治療，對照組口服利培酮治療，觀察8週。採用暘性與陰性癥狀量錶評定臨床療效，副反應量錶評定不良反應。結果治療後兩組暘性與陰性癥狀量錶總分及各因子分均較治療前顯著下降（ P＜0．05或0．01），治療8週末研究組總有效率為83．3％，對照組為81．7％，兩組比較差異無顯著性（χ2＝0．06，P＞0．05）。研究組不良反應髮生率為56．7％，對照組為53．3％，兩組比較差異無顯著性（χ2＝0．13，P＞0．05），但研究組體質量增加、月經改變及泌乳、性欲改變等不良反應髮生率低于對照組。結論哌囉匹隆與利培酮治療首髮精神分裂癥療效顯著，安全性高，依從性好，但哌囉匹隆較少引起內分泌改變和體質量增加，更適用于女性首髮精神分裂癥患者。
목적：탐토고라필륭여리배동치료수발정신분렬증환자적림상료효화안전성。방법장120례수발정신분렬증환자수궤분위량조，연구조구복고라필륭치료，대조조구복리배동치료，관찰8주。채용양성여음성증상량표평정림상료효，부반응량표평정불량반응。결과치료후량조양성여음성증상량표총분급각인자분균교치료전현저하강（ P＜0．05혹0．01），치료8주말연구조총유효솔위83．3％，대조조위81．7％，량조비교차이무현저성（χ2＝0．06，P＞0．05）。연구조불량반응발생솔위56．7％，대조조위53．3％，량조비교차이무현저성（χ2＝0．13，P＞0．05），단연구조체질량증가、월경개변급비유、성욕개변등불량반응발생솔저우대조조。결론고라필륭여리배동치료수발정신분렬증료효현저，안전성고，의종성호，단고라필륭교소인기내분비개변화체질량증가，경괄용우녀성수발정신분렬증환자。
Objective To explore the efficacy and safety of perospirone and risperidone in the treatment of first‐episode schizophrenia .Methods A total of 120 first‐episode schizophrenics were randomly divided into two groups ,research group took orally perospirone and control group did risperidone for 8 weeks .Ef‐ficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the total and each factor scores of the PANSS of both groups lowered more significantly compared with pretreatment (P<0 .05 or 0 .01) ,at the end of the 8th week total effective rate was respectively 83 .3% in research and 81 .7% in con‐trol group ,which showed no significant difference (χ2 =0 .06 ,P>0 .05) .The incidence of adverse reaction was respectively 56 .7% in research and 53 .3% in control group ,which showed no significant difference (χ2 = 0 .13 ,P> 0 .05) ,but the incidences of weight gain ,menstruation change ,lactation and sexuality change were significantly lower in research than in control group .Conclusion Both perospirone and ris‐peridone have an evident effect ,higher safety and better safety in the treatment of first‐episode schizophre‐nia ,but the former causes less endocrine alteration and weight gain and is more suitable to female first‐epi‐sode schizophrenic .
